Oncology Medical News about Non-small cell lung cancer, carboplatin, gemcitabine

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small cell lung cancer treated with carboplatin and gemcitabine
Journal of Clinical Oncology, 08/17/09

Holm B et al. - In a study to analyze the association between the excision repair cross-complementation group 1 (ERCC1) status and overall survival after chemotherapy, it was confirmed that ERCC1 expression is predictive for outcome in pts treated with carboplatin and gemcitabine. Pts with ERCC1-negative tumors had an increased survival vs pts with ERCC1-positive tumors and this difference was mainly attributable to a survival difference among men.

Methods

163 pts were identified with inoperable NSCLC and sufficient tumor tissue for ERCC1 analysis, who had received carboplatin and gemcitabine as first-line treatment.
Immunohistochemistry was used to assess expression of ERCC1.

Results

163 pts were included; 70 (42%) were ERCC1-positive.
Pts treated with carboplatin and gemcitabine and having ERCC1-negative tumors had a significantly increased survival when compared with pts with ERCC1-positive tumors (median survival, 12.0 vs 8.2 mos).
This difference was mainly seen in men, where those with ERCC1-negative tumors had a significantly increased survival vs men with ERCC1-positive tumors (median survival, 11.8 vs 7.9 mos).
Women who were ERCC1-negative did not have a survival advantage over ERCC1-positive women.

<< Previous
Histologic follow-up results in 662 patients with Pap test...

Next >>
Combination therapy with rituximab and intravenous or oral...